Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Drug-Quadruplex Interactions Revealed

May 12, 2008 | A version of this story appeared in Volume 86, Issue 19

[+]Enlarge
Credit: J. Am. Chem. Soc.
Credit: J. Am. Chem. Soc.

A newly obtained X-ray crystal structure shows how the anticancer agent BRACO-19 interacts with its molecular targets, which are human quadruplexes—guanine-rich DNA assemblies of highly defined structure found at chromosome ends (J. Am. Chem. Soc., DOI: 10.1021/ja8016973). The structure reported by the University of London's Stephen Neidle and coworkers could help scientists redesign BRACO-19 to create analogs with lower toxicity and better anticancer action. The BRACO-19 family of acridine compounds, originally conceived and synthesized by Neidle's group, has been the subject of a drug discovery program at the London-based biotechnology firm Antisoma. In 2006, the company halted preclinical development of BRACO-19 analogs because of adverse side effects, although Antisoma has now restarted the program. The structure, obtained by Neidle, Nancy H. Campbell, Gary N. Parkinson, and Anthony P. Reszka, shows BRACO-19 bound to and sandwiched between two adjacent quadruplexes. The structure reveals that "drug binding to quadruplexes can be altogether more complex than we previously thought," Neidle says. It indicates that loop regions on the periphery of the quadruplexes "play active roles in forming binding pockets for particular drug features," he adds, even though the drug was originally designed to bind quadruplex grooves.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.